OCUL
Price
$12.30
Change
-$0.20 (-1.60%)
Updated
Aug 7 closing price
Capitalization
2.14B
94 days until earnings call
RCUS
Price
$9.28
Change
-$0.21 (-2.21%)
Updated
Aug 7 closing price
Capitalization
982.61M
95 days until earnings call
Interact to see
Advertisement

OCUL vs RCUS

Header iconOCUL vs RCUS Comparison
Open Charts OCUL vs RCUSBanner chart's image
Ocular Therapeutix
Price$12.30
Change-$0.20 (-1.60%)
Volume$2.41M
Capitalization2.14B
Arcus Biosciences
Price$9.28
Change-$0.21 (-2.21%)
Volume$1.48M
Capitalization982.61M
OCUL vs RCUS Comparison Chart in %
Loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCUL vs. RCUS commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a Hold and RCUS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (OCUL: $12.30 vs. RCUS: $9.28)
Brand notoriety: OCUL and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 97% vs. RCUS: 160%
Market capitalization -- OCUL: $2.14B vs. RCUS: $982.61M
OCUL [@Biotechnology] is valued at $2.14B. RCUS’s [@Biotechnology] market capitalization is $982.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 3 TA indicator(s) are bullish while RCUS’s TA Score has 5 bullish TA indicator(s).

  • OCUL’s TA Score: 3 bullish, 5 bearish.
  • RCUS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than OCUL.

Price Growth

OCUL (@Biotechnology) experienced а +6.22% price change this week, while RCUS (@Biotechnology) price change was +1.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Reported Earning Dates

OCUL is expected to report earnings on Nov 10, 2025.

RCUS is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.14B) has a higher market cap than RCUS($983M). OCUL YTD gains are higher at: 44.028 vs. RCUS (-37.676). OCUL has higher annual earnings (EBITDA): -176.35M vs. RCUS (-377M). RCUS has more cash in the bank: 997M vs. OCUL (350M). RCUS has less debt than OCUL: RCUS (60M) vs OCUL (76.2M). RCUS has higher revenues than OCUL: RCUS (141M) vs OCUL (59.6M).
OCULRCUSOCUL / RCUS
Capitalization2.14B983M218%
EBITDA-176.35M-377M47%
Gain YTD44.028-37.676-117%
P/E RatioN/AN/A-
Revenue59.6M141M42%
Total Cash350M997M35%
Total Debt76.2M60M127%
FUNDAMENTALS RATINGS
OCUL vs RCUS: Fundamental Ratings
OCUL
RCUS
OUTLOOK RATING
1..100
749
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
51
Fair valued
PROFIT vs RISK RATING
1..100
79100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3656
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (51) in the Pharmaceuticals Major industry is in the same range as OCUL (57) in the Pharmaceuticals Other industry. This means that RCUS’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Profit vs Risk Rating (79) in the Pharmaceuticals Other industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to RCUS’s over the last 12 months.

OCUL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as RCUS (98) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to RCUS’s over the last 12 months.

OCUL's Price Growth Rating (36) in the Pharmaceuticals Other industry is in the same range as RCUS (56) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that RCUS’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OCULRCUS
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 9 days ago
85%
Bearish Trend 9 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMGPX74.50N/A
N/A
ClearBridge International Growth IS
ESMAX17.28N/A
N/A
Invesco EQV Euro Small Company A
QFVOX26.37N/A
N/A
Pear Tree Polaris Foreign Value Ord
GABBX18.10N/A
N/A
Gabelli Dividend Growth AAA
GMAWX22.97N/A
N/A
GMO Small Cap Quality III

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-1.60%
EYPT - OCUL
65%
Loosely correlated
-4.82%
RVMD - OCUL
56%
Loosely correlated
-4.69%
DNLI - OCUL
55%
Loosely correlated
-0.42%
IDYA - OCUL
55%
Loosely correlated
-5.16%
NRIX - OCUL
53%
Loosely correlated
-3.63%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with XNCR. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
-2.21%
XNCR - RCUS
51%
Loosely correlated
-2.27%
IDYA - RCUS
49%
Loosely correlated
-5.16%
ACLX - RCUS
47%
Loosely correlated
-1.24%
TRDA - RCUS
47%
Loosely correlated
-10.92%
OCUL - RCUS
47%
Loosely correlated
-1.60%
More